The CEO, PBR Life Sciences, Ayodeji Alaran in his remarks outlined the critical challenges facing Nigeria’s pharmaceutical ...

The company projects revenue growth of mid- to high single digits in FY26 compared with an 8.5% increase in FY25 ...

Sandoz, CIBA-Geigy, Roche and the Basel hub of the pharmaceutical industry all have their roots in this boom. It wasn’t just Swiss companies that ... trademark and its US assets seized during ...

Pivoting away from US exposure could help investors to hedge against the possible negative effects of Trump's tariffs.

Audits of the non-surgical cosmetics industry are under way to check compliance with legislation at both state and federal ...

That’s not great news for Casey Means, the wellness influencer and author Donald Trump nominated at Kennedy’s suggestion to ...

S&P 500 E-Mini futures (ESM25) are down -0.33%, andJune Nasdaq 100 E-Mini futures (NQM25) are down -0.49% this morning, ...

The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month. But let's face facts -- ...

U.S. President Donald Trump's trade negotiators are pushing the EU to make unilateral tariff reductions on U.S. goods, saying ...

The U.S. Department of Health and Human Services said on Tuesday it would set drug prices pegged to the lowest level paid by ...

2 M&A plays a key role in bringing highly lucrative medications to market, as large pharmaceutical companies often look to invest in young biotechnology companies for their innovative products.

Let us delve into the intricacies of biologics contract manufacturing, explore its definitions, benefits, and the key considerations for pharmaceutical companies seeking to leverage this powerful ...